Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data GOLDENWELL BIOTECH, INC. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
0
0.02
0.05
0
0
0
Cost of revenue
0
0
0.01
0.02
0
0
0
Gross profit
0
0
0.01
0.03
0
0
0
Selling, general and administrative
0
0.01
0.13
General and administrative
0.13
1.01
0.12
0.12
0.11
Operating expenses
0
0.01
-0.13
1.01
0.12
0.12
0.11
Operating income
-0.12
-0.99
-0.12
-0.12
-0.11
Interest expense
0
0
0
0
0.01
0.01
Other non-operating income
0
0
0
0
Pre-tax income
-0
-0.01
-0.12
-0.12
-0.13
Income tax
0
0
0
0
0
0
0
Net income
-0
-0.01
-0.12
-0.99
-0.12
-0.13
-0.3
EPS, basic
0.00
0.00
0.00
EPS, diluted
0.00
0.00
0.00
0.00
0.00
0.00
Shares, basic (weighted)
76.2
80
91.3
Shares, diluted (weighted)
76.2
80
91.3
99
99
99
Balance sheet
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.25
0.25
0.21
0.05
0.05
0.05
0.03
Receivables
0
0
Inventory
0
0.2
0.18
0.17
0.17
0.17
Other current assets
0.01
Total current assets
0.25
Lease right-of-use assets
0
0.05
0.03
0
0
0
Intangible assets
0
0
Total assets
0.25
0.25
0.46
0.25
0.23
0.22
0.04
Accounts payable
0
0.11
0
0
0
0
Accrued liabilities
0
Deferred revenue
0
0
Total current liabilities
0
0
0.16
0
0.1
Long-term debt
0.05
0.17
Lease liabilities
0
0
Other non-current liabilities
0.07
0.19
0.19
Total liabilities
0
0
0.16
0.05
0.14
0.27
0.38
Total debt
0.05
0.17
Paid-in capital
0.25
0.33
0.42
1.3
1.3
1.3
1.3
Retained earnings
-0
-0.01
-0.13
-1.11
-1.23
-1.36
-1.66
Shareholders' equity
0.25
0.25
0.3
0.2
0.08
-0.05
-0.34
Total equity
0.25
0.25
0.3
0.2
0.08
-0.05
-0.34
Total liabilities and equity
0.25
0.25
0.46
0.25
0.23
0.22
0.04
Shares outstanding
80
91.5
91.5
99
99
99
99
Cash flow statement
FY2020
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-0
-0.01
0.12
-0.99
-0.12
-0.13
-0.3
Change in receivables
0
0
0
Change in inventory
0
-0.2
-0.02
0
0
0
Change in payables
0
0.11
-0.11
Cash from operations
-0
-0.01
-0.21
-1.07
-0.11
-0.12
-0.02
Debt issued
0.02
0.07
0.12
Stock issued
0.25
0.01
0.09
0
0
Cash from financing
0.25
0.01
0.17
0.91
0.12
0.12
0
Net change in cash
0.25
0
-0.04
-0.17
0.01
-0
-0.02
Interest paid
0
0
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.69 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
21.8%
Gross profit / revenue.
Operating margin
-208,729.0%
Operating income / revenue.
Net margin
-512,940.0%
Net income / revenue.
Operating cash flow margin
-200,664.0%
Cash from operations / revenue.
Return on assets (ROA)
-973.6%
Net income / average total assets.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-60.4%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-89.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit growth, 1y
-81.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-92.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-83.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-47.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-32.0%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
0.0%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
4.4%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Quick ratio
0.11x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.11x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.00
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1,241,460x
Market cap / revenue.
EV/Sales
1,241,257x
Enterprise value / revenue.
Earnings yield
-0.4%
Net income / market cap (the inverse of P/E).
What was GOLDENWELL BIOTECH, INC.'s revenue in fiscal 2025?
GOLDENWELL BIOTECH, INC. reported revenue of $55.0 for fiscal 2025, 60.4% lower than the year before.
Was GOLDENWELL BIOTECH, INC. profitable in fiscal 2025?
No. It reported a net loss of $296.5K.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.